<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109282</article-id><article-id pub-id-type="publisher-id">ACM-37516</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_66296528.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效观察
  Observation on the Efficacy of Anthracycline Combined with Taxane and Sequential Regimen in Neoadjuvant Chemotherapy of Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>茜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孔</surname><given-names>德志</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>玉华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，肿瘤科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院，胸外科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>1874</fpage><lpage>1882</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    观察蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效差异。回顾性分析2012年1月至2018年12月就诊于我院的405例单侧原发性乳腺癌女性患者的临床资料，按新辅助化疗所应用的方案划分为蒽环类、紫杉类联合组(299例)及蒽环类、紫杉类序贯组(106例)。入组患者都经过至少4个周期的新辅助化疗(neoadjuvant chemotherapy, NAC)。对两组方案的客观缓解率(objective response rate, ORR)和病理完全缓解率(pathologic complete response, pCR)进行比较，并比较不同分子亚型对ORR及pCR的影响。蒽环类、紫杉类联合方案与蒽环类、紫杉类序贯方案的ORR无统计学差异(P = 0.333 &gt; 0.05)，pCR无统计学差异(P = 0.650 &gt; 0.05)。Luminal A型、Luminal B型、Her-2过表达型及三阴型乳腺癌的ORR无统计学差异(P = 0.762 &gt; 0.05)、pCR具有统计学差异(P = 0.003 &lt; 0.05)。蒽环类和紫杉类联合方案与序贯方案疗效相仿，三阴型及Her-2过表达型乳腺癌较Luminal型乳腺癌对新辅助化疗的疗效更佳。
    To study the efficacy of anthracycline combined with taxane and sequential regimen in neoadjuvant chemotherapy of breast cancer, the clinical data of 405 female patients with unilateral primary breast cancer who received treatment in our hospital from January 2012 to December 2018 were analyzed retrospectively. According to the regimens used in neoadjuvant chemotherapy, they were divided into anthracycline combined with taxane group (299 cases) and anthracycline sequential taxane group (106 cases). All patients underwent neoadjuvant chemotherapy (NAC) for at least four cycles. Objective response rate (ORR) and pathologic complete response (pCR) were compared between the two groups, and the effects of different molecular subtypes on ORR and pCR were compared. There was no significant difference in ORR (P = 0.333 &gt; 0.05) and pCR (P = 0.650 &gt; 0.05) between anthracycline combined with taxane regimen and anthracycline sequential taxane regimen; There was no significant difference in ORR (P = 0.762 &gt; 0.05) and significant difference in PCR (P = 0.003 &lt; 0.05) among Luminal A, Luminal B, Her-2 over-expression and triple-negative breast cancers. The efficacy of anthracycline combined with taxane regimen is similar to that of sequential regimen. The efficacy of neoadjuvant chemotherapy in triple-negative and HER-2 over-expression breast cancers is better than that in Luminal breast cancers. 
  
 
</p></abstract><kwd-group><kwd>乳腺癌，新辅助化疗，蒽环类，紫杉类, Breast Cancer</kwd><kwd> Neoadjuvant Chemotherapy</kwd><kwd> Anthracycline</kwd><kwd> Taxane</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>观察蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效差异。回顾性分析2012年1月至2018年12月就诊于我院的405例单侧原发性乳腺癌女性患者的临床资料，按新辅助化疗所应用的方案划分为蒽环类、紫杉类联合组(299例)及蒽环类、紫杉类序贯组(106例)。入组患者都经过至少4个周期的新辅助化疗(neoadjuvant chemotherapy, NAC)。对两组方案的客观缓解率(objective response rate, ORR)和病理完全缓解率(pathologic complete response, pCR)进行比较，并比较不同分子亚型对ORR及pCR的影响。蒽环类、紫杉类联合方案与蒽环类、紫杉类序贯方案的ORR无统计学差异(P = 0.333 &gt; 0.05)，pCR无统计学差异(P = 0.650 &gt; 0.05)。Luminal A型、Luminal B型、Her-2过表达型及三阴型乳腺癌的ORR无统计学差异(P = 0.762 &gt; 0.05)、pCR具有统计学差异(P = 0.003 &lt; 0.05)。蒽环类和紫杉类联合方案与序贯方案疗效相仿，三阴型及Her-2过表达型乳腺癌较Luminal型乳腺癌对新辅助化疗的疗效更佳。</p></sec><sec id="s2"><title>关键词</title><p>乳腺癌，新辅助化疗，蒽环类，紫杉类</p></sec><sec id="s3"><title>Observation on the Efficacy of Anthracycline Combined with Taxane and Sequential Regimen in Neoadjuvant Chemotherapy of Breast Cancer<sup> </sup></title><p>Qian Wu<sup>1</sup>, Dezhi Kong<sup>2</sup>, Lin He<sup>1</sup>, Yuhua Song<sup>1*</sup></p><p><sup>1</sup>Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/2-1571532x4_hanspub.png" /></p><p>Received: Aug. 17<sup>th</sup>, 2020; accepted: Sep. 1<sup>st</sup>, 2020; published: Sep. 8<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/2-1571532x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>To study the efficacy of anthracycline combined with taxane and sequential regimen in neoadjuvant chemotherapy of breast cancer, the clinical data of 405 female patients with unilateral primary breast cancer who received treatment in our hospital from January 2012 to December 2018 were analyzed retrospectively. According to the regimens used in neoadjuvant chemotherapy, they were divided into anthracycline combined with taxane group (299 cases) and anthracycline sequential taxane group (106 cases). All patients underwent neoadjuvant chemotherapy (NAC) for at least four cycles. Objective response rate (ORR) and pathologic complete response (pCR) were compared between the two groups, and the effects of different molecular subtypes on ORR and pCR were compared. There was no significant difference in ORR (P = 0.333 &gt; 0.05) and pCR (P = 0.650 &gt; 0.05) between anthracycline combined with taxane regimen and anthracycline sequential taxane regimen; There was no significant difference in ORR (P = 0.762 &gt; 0.05) and significant difference in PCR (P = 0.003 &lt; 0.05) among Luminal A, Luminal B, Her-2 over-expression and triple-negative breast cancers. The efficacy of anthracycline combined with taxane regimen is similar to that of sequential regimen. The efficacy of neoadjuvant chemotherapy in triple-negative and HER-2 over-expression breast cancers is better than that in Luminal breast cancers.</p><p>Keywords:Breast Cancer, Neoadjuvant Chemotherapy, Anthracycline, Taxane</p><disp-formula id="hanspub.37516-formula7"><graphic xlink:href="//html.hanspub.org/file/2-1571532x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1571532x7_hanspub.png" /> <img src="//html.hanspub.org/file/2-1571532x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>乳腺癌(Breast cancer, BC)是世界上女性最常见的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.37516-ref1">1</xref>]，也是除肺相关恶性肿瘤以外发病率最高的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.37516-ref2">2</xref>]，是女性癌症相关死亡的最主要原因。近年来，BC的发病率逐年升高 [<xref ref-type="bibr" rid="hanspub.37516-ref3">3</xref>]，有研究表明美国每年死于乳腺癌的人数达到4万人 [<xref ref-type="bibr" rid="hanspub.37516-ref4">4</xref>]，其中大部分是死于早期乳腺癌的复发，因此给予女性BC患者标准、有效的治疗显得尤为重要。</p><p>新辅助化疗(NAC)已成为国际公认的乳腺癌标准治疗的重要组成部分。对于局部晚期且手术意愿强烈的患者，NAC可显著提高手术成功率和肿瘤切除率；对于保乳要求高的患者，亦可提供新的解决方案 [<xref ref-type="bibr" rid="hanspub.37516-ref5">5</xref>]。如果新辅助化疗方案有效，在术后设计进一步治疗方案时具有重要指导价值。在乳腺癌患者整个治疗过程中，新辅助化疗扮演着愈来愈重要的角色，国内外已就此达成高度共识。随机临床试验显示NAC获得病理完全缓解的患者较未获得病理完全缓解的患者显示出更好的预后 [<xref ref-type="bibr" rid="hanspub.37516-ref6">6</xref>]，这使得NAC能够快速确定对治疗的反应和体内化疗敏感性成为可能 [<xref ref-type="bibr" rid="hanspub.37516-ref7">7</xref>]。在乳腺癌NAC中，蒽环类和紫杉类是最常用的化疗药物，以蒽环类和紫杉类为基础的化疗方案可使乳腺癌的死亡率降低约三分之一 [<xref ref-type="bibr" rid="hanspub.37516-ref8">8</xref>]。蒽环类和紫杉类在乳腺癌NAC中的效果已受到认可，是目前乳腺癌NAC的标准治疗药物，但如何合理配伍以优化疗效仍是当前乳腺癌NAC研究的热点。目前国际上存在这两种药物联合与序贯应用的不同方案。在临床上两种方案的选择各有利弊，根据临床经验，联合方案一般用于肿块体积较大、局部症状较重、身体一般状况较好的患者；序贯方案一般用于肿块体积不大、局部症状不明显、身体一般情况不理想的患者，但哪种方案在乳腺癌NAC中更优尚无定论。因此，本研究探讨两种方案NAC的疗效及与分子分型的关系，希望为NAC方案的选择和乳腺癌的个体化治疗提供理论依据和参考。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选取2012年1月至2018年12月就诊于青岛大学附属医院乳腺诊疗中心的经病理诊断明确的乳腺癌女性患者。入组标准：①经病理证实为原发性乳腺癌患者；②治疗前未接受放疗、化疗或内分泌治疗；③具有可评价的原发性肿瘤病变；④选用蒽环、紫杉联合或者蒽环、紫杉序贯方案的患者。排除标准：①已发生远处转移者；②无法耐受化疗者；③患有其他恶性肿瘤的患者；④妊娠、哺乳期患者。收集患者的临床资料，包括：年龄、月经史、肿瘤分级(Tumor, T)、腋窝淋巴结、雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人类表皮生长因子受体2(Human epidermal growth factor receptor-2 Her-2)、Ki-67、穿刺病理类型等。</p><p>根据选用化疗方案的不同(蒽环、紫杉联合组与蒽环、紫杉序贯组)将405例患者分为两组(I组：蒽环、紫杉联合组；II组：蒽环、紫杉序贯组)，表1是对两组患者的基线资料进行比较。其中I组299例，II组106例。年龄：25~72岁，其中≤50岁的198例，&gt;50岁的207例；月经状态：未绝经206例，已绝经199例；T：T1期53例，T2期232例，T3-T4期120例；腋窝淋巴结转移情况：阴性49例，阳性356例；ER：阴性136例，阳性269例；PR：阴性192例，阳性213例；Her-2：阴性226例，阳性179例；Ki-67：&lt;20%的61例，≥20%的244例；穿刺病理类型：Luminal A型43例，Luminal B型230例，Her-2过表达型85例，三阴型47例。两组基线资料之间的差异无统计学意义(P &gt; 0.05)。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the baseline data between two group</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >一般资料</th><th align="center" valign="middle" >I组(n = 299)</th><th align="center" valign="middle" >II组(n = 106)</th><th align="center" valign="middle" >c2</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3.129</td><td align="center" valign="middle" >0.077</td></tr><tr><td align="center" valign="middle" >≤50</td><td align="center" valign="middle" >154 (51.5%)</td><td align="center" valign="middle" >44 (41.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >145 (48.5%)</td><td align="center" valign="middle" >62 (58.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >月经状态</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.784</td><td align="center" valign="middle" >0.376</td></tr><tr><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >156 (52.2%)</td><td align="center" valign="middle" >50 (47.2%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >143 (47.8%)</td><td align="center" valign="middle" >56 (52.8%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤分级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3.551</td><td align="center" valign="middle" >0.169</td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >35 (11.7%)</td><td align="center" valign="middle" >18 (17%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >169 (56.5%)</td><td align="center" valign="middle" >63 (59.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T3~T4</td><td align="center" valign="middle" >95 (31.8%)</td><td align="center" valign="middle" >25 (23.6%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >腋窝淋巴结</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.797</td><td align="center" valign="middle" >0.094</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >41 (13.7%)</td><td align="center" valign="middle" >8 (7.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >258 (86.3%)</td><td align="center" valign="middle" >98 (92.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ER</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.113</td><td align="center" valign="middle" >0.737</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >99 (33.1%)</td><td align="center" valign="middle" >37 (34.9%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >阳性</th><th align="center" valign="middle" >200 (66.9%)</th><th align="center" valign="middle" >69 (65.1%)</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >PR</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.260</td><td align="center" valign="middle" >0.610</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >144 (48.2%)</td><td align="center" valign="middle" >48 (45.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >155 (51.8%)</td><td align="center" valign="middle" >58 (54.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Her-2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.649</td><td align="center" valign="middle" >0.104</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >174 (58.2%)</td><td align="center" valign="middle" >52 (49.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >125 (41.8%)</td><td align="center" valign="middle" >54 (50.9%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ki-67</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.571</td><td align="center" valign="middle" >0.210</td></tr><tr><td align="center" valign="middle" >&lt;20%</td><td align="center" valign="middle" >49 (16.4%)</td><td align="center" valign="middle" >12 (11.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥20%</td><td align="center" valign="middle" >250 (83.6%)</td><td align="center" valign="middle" >94 (88.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >分子亚型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3.548</td><td align="center" valign="middle" >0.315</td></tr><tr><td align="center" valign="middle" >Luminal A</td><td align="center" valign="middle" >36 (12%)</td><td align="center" valign="middle" >7 (6.6%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Luminal B</td><td align="center" valign="middle" >166 (55.5%)</td><td align="center" valign="middle" >64 (60.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Her-2过表达</td><td align="center" valign="middle" >60 (20.1%)</td><td align="center" valign="middle" >25 (23.6%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >三阴型</td><td align="center" valign="middle" >37 (12.4%)</td><td align="center" valign="middle" >10 (9.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 两组基线资料比较</p></sec><sec id="s6_2"><title>2.2. 免疫组化的判定及乳腺癌分子亚型的分类</title><p>根据本院病理科医生对穿刺结果的报告记录ER、PR、Her-2、Ki-67等的状态。参照2013年美国ASCO/CAP指南 [<xref ref-type="bibr" rid="hanspub.37516-ref9">9</xref>]，ER、PR阳性定义为肿瘤细胞染色 ≥ 1%，阴性定义为肿瘤细胞染色 &lt; 1%。通过免疫组织化学(IHC)或荧光原位杂交(FISH)评估Her-2的状态，根据染色强度的解释，IHC 3+为Her-2阳性，IHC 1+为阴性，若IHC 2+则需进行FISH基因扩增检测来进一步评估Her-2的状态，FISH检测结果为阳性即为阳性，反之为阴性。将Ki-67阳性细胞染色数 ≥ 20%定义为高表达，Ki-67阳性细胞染色数 &lt; 20%定义为低表达 [<xref ref-type="bibr" rid="hanspub.37516-ref8">8</xref>]。乳腺癌的分子分型将根据原发性乳腺癌临床实践指南 [<xref ref-type="bibr" rid="hanspub.37516-ref8">8</xref>] 的推荐：① Luminal A型：ER和/或PR阳性，Her-2阴性，Ki-67 &lt; 20%；② Luminal B型：ER和/或PR阳性，Her-2阴性，Ki-67 ≥ 20%；ER和/或PR阳性，Her-2阳性，Ki-67无限制；③ Her-2过表达型：ER和PR阴性，Her-2阳性，Ki-67无限制；④ 三阴型：ER和PR阴性，Her-2阴性，Ki-67无限制。</p></sec><sec id="s6_3"><title>2.3. 治疗方案</title><p>I组(蒽环/紫杉联合组，包括TEC和TE两种方案)：TEC方案：多西他赛75 mg/m<sup>2</sup>，静脉滴注，d1；表阿霉素75 mg/m<sup>2</sup>，静脉滴注，d1；环磷酰胺500 mg/m<sup>2</sup>，静脉滴注，d1；21天为一个周期。TE方案：多西他赛75 mg/m<sup>2</sup>，静脉滴注，d1；表阿霉素75 mg/m<sup>2</sup>，静脉滴注，d1；21天为一个周期。I组患者行4~8周期化疗。II组(蒽环/紫杉序贯组)：表阿霉素90 mg/m<sup>2</sup>，静脉滴注，d1；环磷酰胺600 mg/m<sup>2</sup>，静脉滴注，d1，21天为一周期，4周期后序贯至多西他赛90 mg/m<sup>2</sup>，静脉滴注，d1 (或者4周期后序贯至紫杉醇175 mg/m<sup>2</sup>，静脉滴注，d1)，21天为一周期。II组患者行6~8周期化疗。</p></sec><sec id="s6_4"><title>2.4. 疗效评价标准</title><p>根据实体瘤疗效评价标准RECIST (1.1版) [<xref ref-type="bibr" rid="hanspub.37516-ref10">10</xref>] 进行疗效评估：① CR (完全缓解)：所有靶病灶消失，至少维持4周；② PR (部分缓解)：最大肿瘤直径减少30%以上，至少维持4周；③ PD (疾病进展)：最大肿瘤直径增加20%以上或出现新病灶；④ SD (疾病稳定)：肿瘤减小的程度没达到PR，增加的程度也没达到PD水平，介于两者之间。客观缓解(OR) = PR + CR。目前国际上对pCR的定义尚未统一，有研究者将pCR定义为乳腺原发病灶及腋窝淋巴结均无残留浸润性癌，另外也有研究者将pCR定义为乳腺原发病灶无浸润癌成分残留，并未考虑腋窝淋巴结是否残留浸润癌成分的情况 [<xref ref-type="bibr" rid="hanspub.37516-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref13">13</xref>]，本研究中对pCR的定义采用第二种。</p></sec><sec id="s6_5"><title>2.5. 统计分析</title><p>采用SPSS 25.0统计软件进行数据分析，率的比较采用c2检验或者Fisher确切概率法，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 蒽环、紫杉联合与蒽环、紫杉序贯的客观缓解率比较</title><p>I组、II组的ORR分别84.3%、80.2%，两组间ORR无统计学差异(P = 0.333 &gt; 0.05) (表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of ORR between two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >I组(n = 299例)</th><th align="center" valign="middle" >II组(n = 106例)</th><th align="center" valign="middle" >c2</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >ORR</td><td align="center" valign="middle" >252 (84.3%)</td><td align="center" valign="middle" >85 (80.2%)</td><td align="center" valign="middle" >0.938</td><td align="center" valign="middle" >0.333</td></tr><tr><td align="center" valign="middle" >非ORR</td><td align="center" valign="middle" >47 (15.7%)</td><td align="center" valign="middle" >21 (19.8%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 两组客观缓解率比较</p></sec><sec id="s7_2"><title>3.2. 蒽环、紫杉联合与蒽环、紫杉序贯方案的pCR率比较</title><p>I组、II组的pCR率分别为18.7%、20.8%，两组间pCR率无统计学差异(P = 0.650 &gt; 0.05) (表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of pCR between two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >I组(n = 299例)</th><th align="center" valign="middle" >II组(n = 106例)</th><th align="center" valign="middle" >c2</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >pCR</td><td align="center" valign="middle" >56 (18.7%)</td><td align="center" valign="middle" >22 (20.8%)</td><td align="center" valign="middle" >0.206</td><td align="center" valign="middle" >0.650</td></tr><tr><td align="center" valign="middle" >非pCR</td><td align="center" valign="middle" >243 (81.3%)</td><td align="center" valign="middle" >84 (79.2%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 两组pCR率比较</p></sec><sec id="s7_3"><title>3.3. 不同乳腺癌分子亚型NAC后客观缓解率比较</title><p>Luminal A型、Luminal B型、Her-2过表达型、三阴型的ORR分别为79.1%、83.5%、85.9%、80.9%，各组间ORR无统计学差异(P = 0.762) (表4)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of ORR between different molecular subtype</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >ORR</th><th align="center" valign="middle" >非ORR</th><th align="center" valign="middle" >c2</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Luminal A型</td><td align="center" valign="middle" >34 (79.1%)</td><td align="center" valign="middle" >9 (20.9%)</td><td align="center" valign="middle" >1.161</td><td align="center" valign="middle" >0.762</td></tr><tr><td align="center" valign="middle" >Luminal B型</td><td align="center" valign="middle" >192 (83.5%)</td><td align="center" valign="middle" >38 (16.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Her-2过表达型</td><td align="center" valign="middle" >73 (85.9%)</td><td align="center" valign="middle" >12 (14.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >三阴型</td><td align="center" valign="middle" >38 (80.9%)</td><td align="center" valign="middle" >9 (19.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 不同分子亚型NAC后客观缓解率比较</p></sec><sec id="s7_4"><title>3.4. 不同乳腺癌分子亚型NAC后pCR率比较</title><p>Luminal A型、Luminal B型、Her-2过表达型、三阴型的pCR率分别为4.7%、17.4%、23.5%、34.0%，分析发现不同分子亚型的pCR具有统计学差异(P = 0.003 &lt; 0.05) (表5)，Luminal型乳腺癌pCR率远不及Her-2过表达型及三阴型乳腺癌。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of pCR between different molecular subtype</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >pCR</th><th align="center" valign="middle" >非pCR</th><th align="center" valign="middle" >c2</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Luminal A型</td><td align="center" valign="middle" >2 (4.7%)</td><td align="center" valign="middle" >41 (95.3%)</td><td align="center" valign="middle" >14.019</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >Luminal B型</td><td align="center" valign="middle" >40 (17.4%%)</td><td align="center" valign="middle" >190 (82.6%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Her-2过表达型</td><td align="center" valign="middle" >20 (23.5%)</td><td align="center" valign="middle" >65 (76.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >三阴型</td><td align="center" valign="middle" >16 (34.0%)</td><td align="center" valign="middle" >31 (66.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表5. 不同分子亚型NAC后pCR率比较</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>乳腺癌NAC是原发性乳腺癌的重要治疗手段之一，有关乳腺癌NAC的研究已成为各乳腺诊疗中心的热点。NAC可对肿瘤进行降期，将不能手术的患者转变为可手术的患者，通过早期全身治疗消除体内的微转移，改善预后并提供肿瘤化疗敏感性和患者预后指标，在临床上得到广泛的应用。根据NAC时治疗的有效性，对术后复发患者方案的选择具有重要参考价值，减轻患者因原发性耐药在选择治疗方案时的时间及经济压力。与传统辅助化疗相比，能够减少早期临床播散性病变 [<xref ref-type="bibr" rid="hanspub.37516-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref15">15</xref>]。NAC后疗效评价的主要指标是pCR，有研究表明，pCR是长期生存的有效替代指标 [<xref ref-type="bibr" rid="hanspub.37516-ref16">16</xref>]，pCR与生存期的显著延长相关 [<xref ref-type="bibr" rid="hanspub.37516-ref13">13</xref>]，具有NAC适应症的患者可从NAC中获益 [<xref ref-type="bibr" rid="hanspub.37516-ref17">17</xref>]。</p><p>本研究中，蒽环、紫杉联合组的ORR和pCR率分别为84.3%、18.7%，蒽环、紫杉序贯组的ORR和pCR率分别为80.2%、20.8%，两组方案的ORR (c<sup>2</sup> = 0.938 P = 0.333 &gt; 0.05)和pCR率(c<sup>2</sup> = 0.206, P = 0.650 &gt; 0.05)均无统计学差异，这与国内外的研究结果是一致的 [<xref ref-type="bibr" rid="hanspub.37516-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref20">20</xref>]。联合组与序贯组ORR及pCR均没有统计学差异的可能原因如下：首先，虽然两组治疗方案用药周期及顺序不同，但两组选用的均为同两种药物，两种药物针对肿瘤的共同作用均在体内起效，序贯组的后一组药物注射周期内前一组药物并未完全超出药代动力学，这可能直接导致了两组方案对ORR及pCR的影响没有达到统计学差异。其次，影响肿瘤ORR及pCR的因素众多，肿瘤的分期、病理分型、对化疗药物的敏感性都对其有影响，这也可能导致两组方案没有体现出明显的差异。再次，本研究为单中心回顾性研究，样本数量较少，需进行多中心大样本RCT研究进行检验，进一步验证两种方案ORR及pCR有无差异。尽管两种方案的ORR和pCR均没有达到统计学差异，但联合组(84.3%)的ORR要高于序贯组(80.2%)，这提示联合用药对于减小瘤体大小可能要优于序贯用药，比序贯能够更快速地减轻患者局部症状。而序贯组pCR (20.8%)要略高于联合组ORR (18.7%)，可能与序贯组治疗周期(8个周期)高于联合组(6个周期)有关。要求我们在NAC设计有关蒽环、紫杉类药物的方案时，需考虑患者个体的差异设计个体化治疗方案，以求最好地满足患者的利益。有研究表明在不良反应方面，蒽环、紫杉联合方案较蒽环、紫杉序贯方案发生率较高 [<xref ref-type="bibr" rid="hanspub.37516-ref20">20</xref>]。因此，对于一些基础疾病较多的老年患者，我们在选择方案的时候倾向于优先选择蒽环、紫杉序贯方案。但是，对于一些局部症状较重，如：乳房破溃、淋巴水肿、痛感强烈等但身体一般状况可耐受的患者，蒽环、紫杉联合方案可更有效、快速地减小瘤体大小，减轻局部症状，减少患者的痛苦，这种情况下，我们更倾向于选择联合方案。</p><p>影响乳腺癌NAC疗效的因素多种多样，分子亚型被认为与治疗反应、预后密切相关 [<xref ref-type="bibr" rid="hanspub.37516-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref22">22</xref>]。所以本研究中还分析了不同乳腺癌分子亚型的ORR及pCR率，Luminal A型、Luminal B型、Her-2过表达型及三阴型乳腺癌的ORR分别为：79.1%、83.5%、85.9%、80.5%，差异不具有统计学意义(c<sup>2</sup> = 1.161, P = 0.762 &gt; 0.005)；Luminal A型、Luminal B型、Her-2过表达型及三阴型乳腺癌的pCR率分别为4.7%、17.4%、23.5%、34%，差异具有统计学意义(c<sup>2</sup> = 14.019, P = 0.003 &lt; 0.005)。本研究中，不同分子亚型的临床疗效评估与病理疗效评估结果不一致，其结果不一致的可能原因有：首先，根据RECIST1.1版标准，推荐使用核磁共振评价疗效，而本院多数患者因考虑经济等因素拒做核磁共振，多使用B超及钼靶评价疗效；其次有研究发现乳腺癌新辅助化疗的临床评价因病理类型的不同及是否残存脉管瘤栓、是否有神经侵犯，有可能高估或低估治疗疗效；再次，根据病理三维退缩模式，临床病理退缩分为向心性退缩和非向心性退缩，研究表明临床病理退缩模式与分子分型显著相关，这些都使得单纯的临床评价误差增大。研究结果显示三阴型及Her-2过表达型乳腺癌的pCR率比Luminal型乳腺癌明显要高，这与国内外的研究结果也是一致的 [<xref ref-type="bibr" rid="hanspub.37516-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref25">25</xref>]。Luminal型乳腺癌与Her-2过表达型、三阴型乳腺癌的主要区别在于Luminal型乳腺癌ER、PR表达阳性，而Her-2过表达型及三阴型乳腺癌中ER、PR为阴性。有相关文献报道可能正是由于ER、PR状态不同造成pCR率有差异 [<xref ref-type="bibr" rid="hanspub.37516-ref26">26</xref>]，肿瘤的发生发展与原癌基因、抑癌基因的关系密不可分，ER和PR在影响pCR率方面的可能原因是ER和PR的高表达通过抑制肿瘤抑制基因的表达，同时促进细胞增殖/生长和原癌基因的表达 [<xref ref-type="bibr" rid="hanspub.37516-ref20">20</xref>]，从而调节参与乳腺癌患者肿瘤的进展。因此，Luminal型乳腺癌对NAC的疗效不如Her-2过表达型和三阴型乳腺癌对NAC的疗效显著 [<xref ref-type="bibr" rid="hanspub.37516-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.37516-ref21">21</xref>]。</p><p>基于以上结果，蒽环、紫杉联合与蒽环、紫杉序贯两种方案的临床疗效是相仿的。这提示我们，两种治疗方案在乳腺癌NAC中都是可供选择的，应根据患者个体化差异制定个性化治疗方案。而对于不同分子亚型乳腺癌中，Her-2过表达型及三阴型乳腺癌NAC后的疗效较Luminal型的更优，因此在筛选新辅助化疗人群时，分子亚型是筛选的重要因素，我们后期可能还需要寻找能使得Luminal型乳腺癌具有更高敏感性的化疗药物及方案。本研究为单中心回顾性研究，样本数量较少，需进行多中心大样本RCT研究进行检验；此外，本研究只对ORR、pCR等近期疗效进行比较，患者长期生存资料未随访，因此两组方案长期疗效是否有差异需进一步的研究与探索。</p></sec><sec id="s9"><title>同意书</title><p>该研究已获得病人的知情同意。</p></sec><sec id="s10"><title>文章引用</title><p>吴 茜,孔德志,何 林,宋玉华. 蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效观察Observation on the Efficacy of Anthracycline Combined with Taxane and Sequential Regimen in Neoadjuvant Chemotherapy of Breast Cancer[J]. 临床医学进展, 2020, 10(09): 1874-1882. https://doi.org/10.12677/ACM.2020.109282</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37516-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gu, X., Zhang, Y., Chen, L., Guo, J. and Zhang, W.H. (2015) Efficacy of Neo-Adjuvant Chemotherapy with TEC Regimen on Breast Cancer. Cancer Chemotherapy and Pharmacology, 75, 301-308.  
&lt;br&gt;https://doi.org/10.1007/s00280-014-2646-y</mixed-citation></ref><ref id="hanspub.37516-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">US Preventive Services Task Force (2019) Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 322, 857-867. &lt;br&gt;https://doi.org/10.1001/jama.2019.11885</mixed-citation></ref><ref id="hanspub.37516-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Asiri, S., Asiri, A., Ulahannan, S., Alanazi, M., Humran, A. and Hummad, A. (2020) Incidence Rates of Breast Cancer by Age and Tumor Characteristics among Saudi Women: Recent Trends. Cureus, 12, e6664.  
&lt;br&gt;https://doi.org/10.7759/cureus.6664</mixed-citation></ref><ref id="hanspub.37516-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. 
&lt;br&gt;https://doi.org/10.3322/caac.21387</mixed-citation></ref><ref id="hanspub.37516-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chien, A.J., Tripathy, D., Albain, K.S., et al. (2020) MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology, 38, 1059-1069. 
&lt;br&gt;https://doi.org/10.1200/JCO.19.01027</mixed-citation></ref><ref id="hanspub.37516-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rastogi, P., Anderson, S.J., Bear, H.D., et al. (2008) Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of Clinical Oncology, 26, 778-785.  
&lt;br&gt;https://doi.org/10.1200/JCO.2007.15.0235</mixed-citation></ref><ref id="hanspub.37516-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X.S., Ye, G.L., Zhang, C., et al. (2013) Superior Outcome after Neoadjuvant Chemotherapy with Docetaxel, Anthracycline, and Cyclophosphamide versus Docetaxel plus Cyclophosphamide: Results from the NATT Trial in Triple Negative or HER2 Positive Breast Cancer. Breast Cancer Research and Treatment, 142, 549-558.  
&lt;br&gt;https://doi.org/10.1007/s10549-013-2761-1</mixed-citation></ref><ref id="hanspub.37516-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S. and Cardoso, F. (2015) Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 26, V8-V30. &lt;br&gt;https://doi.org/10.1093/annonc/mdv298</mixed-citation></ref><ref id="hanspub.37516-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wolff, A.C., Hammond, M.E., Hicks, D.G., et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 31, 3997-4013. &lt;br&gt;https://doi.org/10.1200/JCO.2013.50.9984</mixed-citation></ref><ref id="hanspub.37516-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.  
&lt;br&gt;https://doi.org/10.1016/j.breast.2014.06.004</mixed-citation></ref><ref id="hanspub.37516-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Untch, M., Konecny, G.E., Paepke, S. and Von Minckwitz, G. (2014) Current and Future Role of Neoadjuvant Therapy for Breast Cancer. The Breast, 23, 526-537. &lt;br&gt;https://doi.org/10.1016/j.breast.2014.06.004</mixed-citation></ref><ref id="hanspub.37516-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bear, H.D., Anderson, S., Smith, R.E., et al. (2006) Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 24, 2019-2027. &lt;br&gt;https://doi.org/10.1200/JCO.2005.04.1665</mixed-citation></ref><ref id="hanspub.37516-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Von Minckwitz, G., Untch, M., Nüesch, E., et al. (2011) Impact of Treatment Characteristics on Response of Different Breast Cancer Phenotypes: Pooled Analysis of the German Neo-Adjuvant Chemotherapy Trials. Breast Cancer Research and Treatment, 125, 145-156. &lt;br&gt;https://doi.org/10.1007/s10549-010-1228-x</mixed-citation></ref><ref id="hanspub.37516-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Herrada, J., Iyer, R.B., Atkinson, E.N., et al. (1997) Relative Value of Physical Examination, Mammography, and Breast Sonography in Evaluating the Size of the Primary Tumor and Regional Lymph Node Metastases in Women Receiving Neoadjuvant Chemotherapy for Locally Advanced Breast Carcinoma. Clinical Cancer Research, 3, 1565-1569.</mixed-citation></ref><ref id="hanspub.37516-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W.C., He, J.S., Song, S.F., Wang, M., Wu, H.S. and Wang, X.M. (2015) Efficacy of TCH/TEC Neoadjuvant Chemotherapy for the Treatment of HER-2-Overexpressing Breast Cancer. Oncology Letters, 9, 1922-1926.  
&lt;br&gt;https://doi.org/10.3892/ol.2015.2912</mixed-citation></ref><ref id="hanspub.37516-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Von Minckwitz, G., Untch, M., Blohmer, J.U., et al. (2012) Definition and Impact of Pathologic Complete Response on Prognosis after Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 30, 1796-1804. &lt;br&gt;https://doi.org/10.1200/JCO.2011.38.8595</mixed-citation></ref><ref id="hanspub.37516-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Vila, J., Teshome, M., Tucker, S.L., Woodward, W.A., Chavez-MacGregor, M., Hunt, K.K. and Mittendorf, E.A. (2017) Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-Regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery, 265, 574-580.  
&lt;br&gt;https://doi.org/10.1097/SLA.0000000000001492</mixed-citation></ref><ref id="hanspub.37516-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">胡赛男, 俞乔, 胡亦钦, 等. EC序贯P剂量密集方案与TEC方案在乳腺癌新辅助化疗中的疗效比较[J]. 临床肿瘤学杂志, 2015, 20(4): 327-332.</mixed-citation></ref><ref id="hanspub.37516-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">凌丰军. EC序贯P剂量密集方案与TEC方案在乳腺癌新辅助化疗中的疗效分析[J]. 国际医药卫生导报, 2016, 22(19): 2995-2998.</mixed-citation></ref><ref id="hanspub.37516-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Gogia, A., Raina, V., Deo, S.V., et al. (2014) Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: Institutional Experience. Asian Pacific Journal of Cancer Prevention, 15, 1989-1992.  
&lt;br&gt;https://doi.org/10.7314/APJCP.2014.15.5.1989</mixed-citation></ref><ref id="hanspub.37516-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Xu, Z.G., Zhang, Z.Y., Wen, G.F., Sun, J.X. and Han, F. (2018) Efficacy and Safety of TE/TEC/Intensive Paclitaxel Neoadjuvant Chemotherapy for the Treatment of Breast Cancer. Oncology Letters, 17, 907-912. 
&lt;br&gt;https://doi.org/10.3892/ol.2018.9658</mixed-citation></ref><ref id="hanspub.37516-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Houssami, N., Macaskill, P., Von Minckwitz, G., Marinovich, M.L. and Mamounas, E. (2012) Meta-Analysis of the Association of Breast Cancer Subtype and Pathologic Complete Response to Neoadjuvant Chemotherapy. European Journal of Cancer, 48, 3342-3354. &lt;br&gt;https://doi.org/10.1016/j.ejca.2012.05.023</mixed-citation></ref><ref id="hanspub.37516-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Díaz-Casas, S.E., Castilla-Tarra, J.A., Pena-Torres, E., et al. (2019) Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort. The Oncologist, 24, e1360-e1370.  &lt;br&gt;https://doi.org/10.1634/theoncologist.2019-0300</mixed-citation></ref><ref id="hanspub.37516-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Stamatovic L, Susnjar S, Gavrilovic D, et al. (2018) The Influence of Breast Cancer Subtypes on the Response to Anthracycline Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. Journal of BUON, 23, 1273-1280.</mixed-citation></ref><ref id="hanspub.37516-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Subbiah, S., Gopu, G., Senthilkumar, P. and Muniasamy, P (2017) Molecular Subtypes as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Indian Journal of Cancer, 54, 652-657.  
&lt;br&gt;https://doi.org/10.4103/ijc.IJC_238_17</mixed-citation></ref><ref id="hanspub.37516-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lindström, L.S., Karlsson, E., Wilking, U.M., et al. (2012) Clinically Used Breast Cancer Markers Such as Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable throughout Tumor Progression. Journal of Clinical Oncology, 30, 2601-2608. &lt;br&gt;https://doi.org/10.1200/JCO.2011.37.2482</mixed-citation></ref></ref-list></back></article>